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Phase II trial of pemetrexed and gemcitabine as first-line 
chemotherapy for elderly and/or poor performance status patients 
with stage iiib/iv non-small cell lung cancer (NSCLC)
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Background: The combination of Pemetrexed (PEM) and Gemcitabine 
(GEM) in the treatment of locally advanced or metastatic NSCLC has 
shown synergy in both preclinical and clinical studies with a favorable 
toxicity proﬁle compared to other doublets. Late-stage and symptomat-
ic diagnosis in elderly patients remains an increasingly common prob-
lem. This study was designed to evaluate the efﬁcacy of this doublet 
as ﬁrst-line therapy for advanced NSCLC in the most difﬁcult to treat 
patients, i.e. older patients and those with poor performance status. The 
goal of this novel doublet regimen is to preserve the activity of two-
drug combinations while minimizing toxicity in an ‘at-risk’ population.
Methods: Patients with age > 65 and ECOG 0-2 or age < 65 and 
ECOG of 2, with locally advanced or metastatic (measurable stage 
IIIB/IV) NSCLC by RECIST criteria were treated with biweekly cycles 
of PEM 500mg/m2 IV over 10 minutes, followed by GEM 1500 mg/m2 
IV over 30 minutes on Day 1. Cycles were repeated every 2 weeks with 
a maximum of 12 cycles for stable or responding patients. All patients 
received vitamin B12 1000 µg and folic acid 1000 mg 7 days prior to 
the initiation of treatment and continued through treatment.
Results: 45 patients were enrolled to this study. The median age is 72 
(range 46-88). Five patients had stage IIIB and 40 stage IV, median 
number of sites of disease is 2. 62% are male. Patient performance 
status was as follows: ECOG 0=5, ECOG 1=27, ECOG 2=13 patients. 
Overall, 22 pts experienced a Grade 3 or 4 AE. Seven patients had 
grade 3 or 4 neutropenia with 2 patients having febrile neutropenia. 
There were 2 patients with grade 3 or 4 anemia, and one with throm-
bocytopenia. 30 patients were evaluable for best overall response, with 
1 achieving CR (3%), 6 with PR (20%), 16 with SD (53%) and 7 with 
PD (23%). Overall, clinical beneﬁt (CR+PR+SD) was seen in 76% of 
patients. 
Conclusion: Pemetrexed and Gemcitabine in combination on a 
biweekly schedule has substantial activity with a favorable toxicity 
proﬁle for elderly patients with advanced NSCLC. Overall response 
rates and clinical beneﬁts are comparable to contemporary platinum 
containing doublet regimens.
P2-317 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4  
Biweekly paclitaxel as second-line treatment in advanced non-
small-cell-lung-cancer (NSCLC). A phase II study of the Lung 
Cancer Galician Group
Vázquez-Estévez, Sergio1 Fírvida, José Luis2 Huidobro, Gerardo3 León, 
Luis4 Lázaro, Martín5 Pérez, Eva2 Álvarez, Elena1 Casal, Joaquín3 
Salgado, Mercedes2 Mel, José Ramón1 
1 Complexo Hospitalario Xeral-Calde, Lugo, Spain 2 Complexo Hos-
pitalario de Ourense, Ourense, Spain 3 Hospital do Meixoeiro, Vigo, 
Spain 4 Complexo Hospitalario Universitario de Santiago, Santiago de 
Compostela, Spain 5 Complexo Hospitalario Xeral-Cíes, Vigo, Spain 
Background: Paclitaxel is an active drug for NSCLC. Our purpose 
was to evaluate the efﬁcacy and toxicity of biweekly administration of 
this drug in previously treated patients with advanced NSCLC.
Methods: Patients with stage IIIB and IV NSCLC, which progressed 
after or during ﬁrst-line chemotherapy, measurable disease, ECOG 
PS=0-1 and adequate organ function were included. Paclitaxel was 
administered at 150 mg /m2 iv, days 1 and 14, every 28 days, for a 
maximum of six cycles. Both, toxicity and efﬁcacy analyses, were 
performed on the intent-to-treat (ITT) population.
Results: Between September 2004 and November 2006, 45 patients 
(M/F, 42/3) were included, with median age 62 years (39-79). Tumor 
histology mainly included epidermoid (42.2%) and adenocarcinoma 
(35.6%). Tumor stage was IIIB (24.4%) and IV (75.6%). Median 
number of metastatic lesions was 1 (57.8%), located mainly in lymph 
nodes (44.4%), lung (33.3%), adrenal glands (20%) and bone (13.3%). 
Previous chemotherapy included platinum (80%), docetaxel (64.4%) 
and gemcitabine (57.8%). A total of 251 cycles (median 5, range 1-6) 
were administered. Median relative dose intensity was 96.2%. Toxicity: 
Grade III/IV hematologic toxicities per patient were neutropenia (2.3%) 
and anemia (2.3%). Grade III/IV non-hematologic toxicities were 
asthenia (2.3%), arthralgias/myalgias (2.3%) and peripheral neuropathy 
(2.3%). Efﬁcacy: Of 45 ITT patients. 9 achieved PR, 11 SD and 17 pro-
gressed, resulting in an ORR of 20% (95%CI: 8.3-31.7%). 7 patients 
could not be evaluated due to early withdrawal (4 tumor-related exitus, 
1 PS deterioration, 1 hypersensibility reaction and 1 loss of follow-up). 
With an average follow-up time of 286 days, median TTP and OS were 
174 days (95%CI: 137.6-210.4) and 289 days (95%CI: 140.5-437.4), 
respectively.
Conclusions: Biweekly paclitaxel is an active and very well tolerated 
regimen in previously treated patients with advanced NSCLC. 
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Activity of intravenous Topotecan in patients with advanced non-
small cell lung cancer pre-treatred with platinum and taxanes: 
Results of the first analysis
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Background: Topotecan, a semi-synthetic camptothecin analogue 
with topoisomerase I interaction has shown to be an active agent in the 
treatment of advanced refractory lung cancer and ovarian cancer. In 
this report, experience with this drug is described when used as a single 
agent in patients with advanced NSCLC refractory to chemotherapy 
regimens containing at least platinum and taxanes.
Material and Methods: twenty-four patients (pts) with NSCLC refrac-
tory to previous chemotherapy and KI ≥60% were included in the study 
showing the following features: median age of 52 years (range 43-69) 
and karnofsky PS of 70 (50-80), 21 were male and 3 female. Fifteen 
(62 %) pts had adenocarcinoma, six (25%) squamous cell and three 
(13%) undifferentiated carcinoma. The median number of disease sites 
and prior regimens received were two in both cases. Topotecan was 
given at a dose of 1.25 mg/m2 I.V. daily for ﬁve days, repeated every 21 
days until progression disease, maximal response or intolerable toxicity 
occurred.
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Results: After 52 cycles administered, pts received a median of 2 
cycles of treatment (1-6). All patients except one were considered 
evaluable for toxicity, with the recording of ﬁve episodes of (22%) nau-
sea/vomiting grade 1-2 and one (4%) of asthenia grade 1. Four (17%) 
patients developed anaemia grade 2-3 and neutropenia grade1. Two 
additional patients (9%) had neutropenia grade 2 and one (4%) grade 
V. Among twenty evaluable pts for activity, one (4%) showed partial 
response, seven (29%) stable disease and twelve (50%) progression dis-
ease. Median time to progression and overall survival are 54 (12-210) 
and 60 (12-485) days respectively.
Conclusion: At this time of evaluation, intravenous Topotecan with 
this schedule and dose shows promising activity. The accrual still 
continues until the planned sample size following the Simon Two-stage 
design.
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Taxotere as salvage chemotherapy in Chinese patients with 
advanced NSCLC who have failed or relapsed after the gefitinib 
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Background: This Phase II study was conducted to evaluate the ef-
ﬁcacy and toxicity of docetaxel single agent in salvage therapy for 
patients with advanced non-small cell lung cancer (NSCLC) who failed 
to respond or relapsed after the geﬁtinib. 
Methods: Patients with histologically conﬁrmed and progressive 
NSCLC after geﬁtinib were eligible for this study. Performance status 
of 0-1 and adequate organ function were required. Patients were treated 
with docetaxel 75 mg/m(2) intravenously for 30 min repeated every 3 
weeks until disease progression or intolerant toxicity. 
Results: Twenty patients were eligible for this study. The TTP for 
iressa was 12 months. Average 2.9 cycles taxotere were given. Hema-
tologic toxicity was mild and with the major toxicity of anemia and 
peripheral neuropathy. The overall response rate (ORR) was 15% and 
disease control rate was 40%. The median survival time (MST) for all 
patients was 542 days (95% CI, 238.2-845.7), TTP was 3.5 months and 
the 1 year survival was 50.2%. 
Conclusions: Docetaxel appeared to be well tolerated as salvage 
therapy for patients with NSCLC who failed to geﬁitinib. 
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Marked response to a cisplatin/docetaxel/temozolomide 
combination in a heavily pre-treated lung cancer patient with a 
metastatic large cell neuroendocrine tumour.
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Introduction: Large cell neuroendocrine carcinoma (LCNEC) is rare 
and differs from other non-small cell lung carcinomas (NSCLC) in that 
it has a particularly aggressive clinical behaviour with poor prognosis. 
We report a dramatic response in body and brain metastases in a heav-
ily pre-treated LCNEC patient receiving a fourth-line combination of 
cisplatin / docetaxel / temozolomide. 
Case Report: A 52-year-old female initially presented with increasing 
breathlessness and superior vena cava obstruction. Histology showed 
LCNEC. Computed tomography showed bulky mediastinal disease. 
Over the next 6 months she received two lines of chemotherapy [cis-
platin / etoposide (stable disease), followed by carboplatin / paclitaxel 
/ radiotherapy (good partial response)]. She progressed 8 months from 
diagnosis with brain metastases (one 5cm diameter). She had a partial 
response to whole brain radiotherapy, but soon after completion she 
was commenced on geﬁtinib for progressive intraabdominal disease. 
She progressed on geﬁtinib with marked clinical deterioration and mas-
sive radiological progression in mediastinum, liver, adrenal and brain 
(12 months from presentation). After a request for more treatment a cis-
platin, docetaxel and temozolomide triplet combination was adminis-
tered [cisplatin 40mg/m2 iv day 1; docetaxel 25 mg/m2 iv days 1, 8, 15; 
temozolomide 150mg/m2 orally days 1-5, every 4 weeks]. The regimen 
was based on a single previous case report in metastatic NSCLC and 
the patient received four cycles of treatment. An excellent symptomatic 
and radiological response (including the brain metastases) was seen, 
with a marked improvement in her quality of life that enabled her to re-
turn to full activity. Unfortunately the disease started to progress again 
four months later and the patient died 20 months from presentation.
Discussion: LCNEC is a rare tumour. The tumour is traditionally 
considered to fall within the category of poorly differentiated NSCLC. 
However, outcomes are similar to SCLC, including a propensity for 
early brain metastases. This is the second report in the literature on the 
use of this speciﬁc chemotherapy combination in NSCLC and the ﬁrst 
report of this cisplatin / docetaxel / temozolomide regimen in LCNEC. 
This triplet is a well-tolerated novel outpatient combination chemother-
apy regimen that treats both systemic and intracranial disease. 
The growing evidence form case series and phase II trials on the use 
of temozolomide containing regimens in patients with reccurent or 
progressive brain metastases from solid tumours will be reviewed. In 
patients who have failed WBRT palliative care was usually the only 
available management option. For ﬁt patients temozolomide singly or 
preferably in combination may offer a real alternative. 
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Efficacy of cisplatin and vinorelbine in patients with metastatic 
NSCLC
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Background: Chemotherapy for advanced NSCLC has gained 
widespread acceptance since it was demonstrated that cisplatin-based 
chemotherapy improved survival and quality of life.The aim of this 
study is to evaluate the feasibility in terms of overall survival, response 
rate and toxicity of the cisplatin-vinorelbine in Turkish patients with 
metastatic NSCLC.
Methods: In this prospective study, ECOG performance 0-1, che-
motherapy-naive stage IV NSCLC patients (pts) were treated with 
cisplatin (75 mg/m2, d1, IV) and vinorelbine (30 mg/m2, d1and d8, IV) 
every 21 days until progesion or unacceptable toxicity for a maximum 
of 6 cycles in single center. Tumor responses were evaluated by WHO 
criteia. Survival was calculated with the Kaplan-Meier method. Eight 
